suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)
Status:
Recruiting
Trial end date:
2022-04-15
Target enrollment:
Participant gender:
Summary
In the SAVE study patients with lower respiratory tract infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious
respiratory failure will be detected using the suPAR biomarker. They will begin early
treatment with anakinra in the effort to prevent progression in serious respiratory failure.
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Treatments:
Interleukin 1 Receptor Antagonist Protein Sulfamethoxazole Trimethoprim